The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain-specific MMP highly expressed in cerebellum.
Abstract
The matrix metalloproteinase (MMP) family, comprising more than 20 isoforms, modulates the extracellular milieu by degrading extracellular matrix (ECM) proteins. Because MMP is one of the few groups of proteinases capable of hydrolysing insoluble fibrillar proteins, they are likely to play crucial roles in regulating both normal and pathophysiological processes in the brain. However, little is yet known about their possible neuronal functions due presumably to their unusual redundancy and to the absence of a complete catalogue of isoforms. As an initial step in understanding the MMP system in the brain, we analysed an expression spectrum of MMP in rat brain using RT‐PCR and discovered a novel brain‐specific MMP, MT5‐MMP. MT5‐MMP was the predominant species among the nongelatinase‐type isoforms in brain. MT5‐MMP, present in all brain tissues examined, was most strongly expressed in cerebellum and was localized in the membranous structures of expressing neurons, as assessed biochemically and immunohistochemically. In cerebellum, its expression was regulated developmentally and was closely associated with dendritic tree formation of Purkinje cells, suggesting that MT5‐MMP may contribute to neuronal development. Furthermore, its stable postdevelopmental expression and colocalization with senile plaques in Alzheimer brain indicates possible roles in neuronal remodeling naturally occurring in adulthood and in regulating pathophysiological processes associated with advanced age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MT5-MMP was detected in neurons and around senile plaques in the brains of AD patients.
“MT5-MMP was detected in neurons and around senile plaques in the brains of AD patients (Sekine-Aizawa et al., 2001) and it was later suggested to cleave APP, yielding a fragmentation profile similar to that of MT1- and MT3-MMP (Ahmad et al., 2006).”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Sekine-Aizawa et al., 2001
Citations
Cites
Backstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331 · cited 2×
“This possibility follows from studies showing that MMP-2 and MMP-9 proteolyse synthetic Ab peptides (Miyazaki et al., 1993; Backstrom et al., 1996).”
Background
Flagged first, then by citations
Research works printed but not linked: 36
- 10.1083/jcb.119.5.1287 · DOI
- 10.1073/pnas.93.6.2448 · DOI
- 10.1002/cne.901450305 · DOI
- 10.1002/cne.901450402 · DOI · Paper page
- 10.1074/jbc.273.36.23004 · DOI
- 10.1016/s0166-2236(96)01030-2 · DOI · Paper page
- Iwata N., 2000, Identification of the major Aβ1−42‐degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition, Nature Med., 6, 143, 10.1038/72237 · DOI · Paper page
- 10.1016/S0006-8993(00)02035-7 · DOI
- Joachim C.L., 1989, Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease, Am. J. Pathol., 135, 309
- 10.1016/S1367-5931(98)80122-1 · DOI
- 10.1083/jcb.133.3.667 · DOI
- Llano E., 1999, Identification and characterization of human MT5‐MMP, a new membrane‐bound activator of progelatinase A overexpressed in brain tumors, Cancer Res., 59, 2570
- 10.1038/362839a0 · DOI
- 10.1016/s0955-0674(99)00022-8 · DOI
- Murphy G., 1993, Proteolysis and Protein Turnover., 25
- Nagase H., 1997, Activation mechanisms of matrix metalloproteinases, Biol. Chem., 378, 151
- 10.1006/jmbi.1999.3492 · DOI
- 10.1074/jbc.274.13.8925 · DOI
- 10.1002/cne.901410303 · DOI
- Saido T.C., 2000, Degradation of amyloid‐β peptide: a key to Alzheimer pathogeneis, prevention, and therapy, Neurosci. News, 5, 52
- Saido T.C., 2000, Neuroscientific Basis of Dementia.
- 10.1016/0896-6273(95)90301-1 · DOI · Paper page
- 10.1093/oxfordjournals.jbchem.a123723 · DOI
- 10.1146/annurev.cb.04.110188.000521 · DOI
- Sambrook J., 1989, A Laboratory Manual.
- 10.1083/jcb.127.1.187 · DOI
- 10.1016/s0962-8924(98)01363-4 · DOI · Paper page
- 10.1073/pnas.76.9.4350 · DOI
- 10.1523/JNEUROSCI.20-11-03937.2000 · DOI
- 10.1523/JNEUROSCI.19-12-04994.1999 · DOI
- 10.1523/JNEUROSCI.20-05-01657.2000 · DOI
- 10.1016/S0092-8674(00)80429-8 · DOI
- 10.1007/s004010050350 · DOI
- Yamaguchi H., 1989, Electron micrograph of diffuse plaques: Initial stage of senile plaque formation in the Alzheimer brain, Am. J. Pathol., 135, 593
- 10.1016/s0166-2236(97)01169-7 · DOI
- 10.1007/s004010050904 · DOI
Cited by
Sorted by citations
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
η-Secretase processing of APP inhibits neuronal activity in the hippocampus
Willem, M., Tahirovic, S., Busche, M. A., Ovsepian, S. V., Chafai, M., Kootar, S., Hornburg, D., Evans, L. D. B., Moore, S., Daria, A., et al. (2015) · Nature · doi:10.1038/nature14864 · Cited by 398
MMPs in learning and memory and neuropsychiatric disorders
Beroun, A., Mitra, S., Michaluk, P., Pijet, B., Stefaniuk, M., & Kaczmarek, L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03180-8 · Cited by 207
Shaping Synapses by the Neural Extracellular Matrix
Ferrer-Ferrer, M., & Dityatev, A. (2018) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2018.00040 · Cited by 169
Matrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges
Zipfel, P., Rochais, C., Baranger, K., Rivera, S., & Dallemagne, P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00352 · Cited by 94
García-González, L., Pilat, D., Baranger, K., & Rivera, S. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00244 · Cited by 88
Kelly, E. A., Russo, A. S., Jackson, C. D., Lamantia, C. E., & Majewska, A. K. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00369 · Cited by 48
Metadata
- Authors
- Sekine‐Aizawa, Y., Hama, E., Watanabe, K., Tsubuki, S., Kanai‐Azuma, M., Kanai, Y., Arai, H., Aizawa, H., Iwata, N., & Saido, T. C.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2001-03
- Volume
- 13
- Issue
- 5
- Pages
- 935-948
- ISSN
- 0953-816X
- 1460-9568
- Cited by
- 97
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review